These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 16781665)

  • 21. Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells.
    Yuan YL; Zhou XH; Song J; Qiu XP; Li J; Ye LF
    J Laryngol Otol; 2008 Sep; 122(9):952-60. PubMed ID: 17908353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo.
    Zhang X; Deng HX; Zhao X; Su D; Chen XC; Chen LJ; Wei YQ; Zhong Q; Li ZY; He X; Yi T
    Oncology; 2009; 77(1):22-32. PubMed ID: 19440000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antisense oligodeoxynucleotide targeting HER2 mRNA sensitized docetaxel in breast cancer treatment.
    Sun J; Xu Y; Song S; Wu Z; Duan H
    Pharm Biol; 2011 Nov; 49(11):1167-72. PubMed ID: 22014264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of RNAi-mediated STAT3 gene inhibition on metastasis of human pancreatic cancer cells].
    Gao Z; Huang C; Qiu ZJ; Jiang T; Zhu L; Cao J; Zhang F; Huang KJ
    Zhonghua Wai Ke Za Zhi; 2008 Jul; 46(13):1010-3. PubMed ID: 19035205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer.
    Li JY; Ou ZL; Yu SJ; Gu XL; Yang C; Chen AX; Di GH; Shen ZZ; Shao ZM
    Breast Cancer Res Treat; 2012 Feb; 131(3):837-48. PubMed ID: 21479551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin.
    Shinohara H; Morita S; Kawai M; Miyamoto A; Sonoda T; Pastan I; Tanigawa N
    J Surg Res; 2002 Feb; 102(2):169-77. PubMed ID: 11796015
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells.
    Li C; Cao S; Liu Z; Ye X; Chen L; Meng S
    Int J Cancer; 2010 Oct; 127(7):1507-16. PubMed ID: 20063318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance.
    Meyer DS; Aceto N; Sausgruber N; Brinkhaus H; Müller U; Pallen CJ; Bentires-Alj M
    Oncogene; 2014 Jan; 33(3):398-402. PubMed ID: 23318421
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Downregulation of HER2 by adenovirus-mediated RNA interference and its inhibitory effect on growth of SKBR3 breast cancer cell].
    Cheng LS; Zha Z; Xi JJ; Jiang B; Liu J; Yao XB
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Aug; 23(8):691-5. PubMed ID: 17618556
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
    Dou S; Yao YD; Yang XZ; Sun TM; Mao CQ; Song EW; Wang J
    J Control Release; 2012 Aug; 161(3):875-83. PubMed ID: 22762887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Establishment of primary Her-2 over- expression human breast cancer cell model].
    Wang LJ; Zhao Y; Xiao HW; Bai E; Dong C; Yang T; Yang AG; Zhu Q
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Oct; 27(10):1148-50. PubMed ID: 22238824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combinational RNAi gene therapy of hepatocellular carcinoma by targeting human EGFR and TERT.
    Hu Y; Shen Y; Ji B; Wang L; Zhang Z; Zhang Y
    Eur J Pharm Sci; 2011 Mar; 42(4):387-91. PubMed ID: 21238587
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [siRNA-mediated inhibition of ErbB2 expression and its effect on breast cancer cell growth].
    Jiang K; Yang ZH; Wang ZY; Xu XJ; Cheng L; Zhang H; Han YJ; Ye QN
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2011 Mar; 27(3):257-9. PubMed ID: 21419042
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new inducible RNAi xenograft model for assessing the staged tumor response to mTOR silencing.
    Ke N; Zhou D; Chatterton JE; Liu G; Chionis J; Zhang J; Tsugawa L; Lynn R; Yu D; Meyhack B; Wong-Staal F; Li QX
    Exp Cell Res; 2006 Sep; 312(15):2726-34. PubMed ID: 16765945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tumor suppression of a constitutively active caspase-3 in the SKBr-3 breast carcinoma xenograft mice model].
    Bao W; Zhang LH; Jia LT; Qu P; Wang CJ; Yang AG
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):23-6. PubMed ID: 15182614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 4-Epidoxycycline: an alternative to doxycycline to control gene expression in conditional mouse models.
    Eger K; Hermes M; Uhlemann K; Rodewald S; Ortwein J; Brulport M; Bauer AW; Schormann W; Lupatsch F; Schiffer IB; Heimerdinger CK; Gebhard S; Spangenberg C; Prawitt D; Trost T; Zabel B; Sauer C; Tanner B; Kolbl H; Krugel U; Franke H; Illes P; Madaj-Sterba P; Bockamp EO; Beckers T; Hengstler JG
    Biochem Biophys Res Commun; 2004 Oct; 323(3):979-86. PubMed ID: 15381096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA interference (RNAi)-mediated vascular endothelial growth factor-C (VEGF-C) reduction interferes with lymphangiogenesis and enhances epirubicin sensitivity of breast cancer cells.
    Sun P; Gao J; Liu YL; Wei LW; Wu LP; Liu ZY
    Mol Cell Biochem; 2008 Jan; 308(1-2):161-8. PubMed ID: 17938864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A mathematical model for the effects of HER2 over-expression on cell cycle progression in breast cancer.
    Eladdadi A; Isaacson D
    Bull Math Biol; 2011 Dec; 73(12):2865-87. PubMed ID: 21814880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
    Falkenberg N; Anastasov N; Höfig I; Bashkueva K; Lindner K; Höfler H; Rosemann M; Aubele M
    Mol Oncol; 2015 Jan; 9(1):282-94. PubMed ID: 25241146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2.
    Hogrefe RI; Lebedev AV; Zon G; Pirollo KF; Rait A; Zhou Q; Yu W; Chang EH
    Nucleosides Nucleotides Nucleic Acids; 2006; 25(8):889-907. PubMed ID: 16901821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.